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A B S T R A C T
Besides altering its own expression during cell transformation, Annexin A2 is upregulated during the progression
of many cancer types and also plays key roles during viral infection and multiplication. Consequently, there has
been great interest in Annexin A2 as a potential drug target. The successful design of efficient in vivo delivery
systems constitutes an obstacle in full exploitation of antisense and RNA-cleaving technologies for the knock-
down of specific targets. Efficiency is dependent on the method of delivery and accessibility of the target. Here,
hairpin ribozymes and an antisense RNA against rat annexin A2 mRNA were tested for their efficiencies in a T7-
driven coupled transcription/translation system. The most efficient ribozyme and antisense RNA were subse-
quently inserted into a retroviral vector under the control of a tRNA promoter, in a cassette inserted between
retroviral Long Terminal Repeats for stable insertion into host DNA. The Phoenix package system based on
defective retroviruses was used for virus-mediated gene transfer into PC12 cells. Cells infected with the ribo-
zyme-containing particles died shortly after infection. However, the same ribozyme showed a very high catalytic
effect in vitro in cell lysates, explained by its loose hinge helix 2 region. This principle can be transferred to other
ribozymes, such as those designed to cleave the guide RNA in the CRISPR/Cas9 technology, as well as to target
specific viral RNAs. Interestingly, efficient down-regulation of the expression of Annexin A2 by the antisense
RNA resulted in up-regulation of Annexin A7 as a compensatory effect after several cell passages. Indeed,
compensatory effects have previously been observed during gene knock-out, but not during knock-down of
protein expression. This highlights the problems in interpreting the phenotypic effects of knocking down the
expression of a protein. In addition, these data are highly relevant when considering the effects of the CRISPR/
Cas9 approach.
1. Introduction
Annexin A2 (AnxA2) is a multifunctional protein [1–4] participating
in many cellular processes, such as exocytosis [5,6], endocytosis
[7–10], exophagy [11], phagocytosis [12], actin dynamics [13,14],
specific mRNA transport and translation [15–17], DNA repair [18],
replication [19] and transcription [20], as well as cell-cell contact, cell
adhesion [21,22] and migration [23]. The discrimination between these
cellular processes is mediated by its post-translational modifications,
subcellular localisation and specific ligand interactions [24–26]. AnxA2
is a key protein in tumour proliferation and progression, related to its
roles in tumour cell adhesion, proliferation and migration, which fa-
cilitate metastasis and neo-angiogenesis [27]. It is therefore not sur-
prising that the expression of AnxA2 is modulated in several cancer
types, being upregulated in e.g. hepatocellular [28], colorectal [29],
and gastric carcinoma [30], pancreatic [31], lung [32] and breast [33],
as well as glioma [34] cancers. Upregulation of AnxA2 correlates with
enhanced cancer progression and poor prognosis [30,35], due to in-
creased tumour recurrence and resistance to therapy [31,36–39]. To
influence cancer progression, it would therefore be beneficial to reduce
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the expression of AnxA2 back to normal physiological levels. Further-
more, since AnxA2 is ubiquitously expressed, it would be highly ad-
vantageous to selectively regulate its expression in cancer cells to avoid
severe side effects. Viruses have the ability to target specific cells by
recognising their cell surface proteins. Thus, viruses loaded with cata-
lytic or antisense RNAs could be used to knock-down the expression of
the protein of interest – in this case, AnxA2 – in cancer cells.
Ribozymes are small catalytic RNA molecules that possess sequence-
specific RNA cleavage activity and can inactivate the expression of
specific gene products. Ribozymes have been successfully used to target
and destroy viral and cellular RNAs both in cell culture and animal
model systems [40]. Successful use of ribozymes to knock-down target
gene expression is dependent on a number of factors, including target
site selection/availability, ribozyme gene delivery, expression, stability
and intracellular localisation. Notably, similar considerations are im-
portant for the use of the CRISPR/Cas9 system. A variety of natural
ribozyme motifs have been identified. Naturally occurring ribozymes
are the self-splicing group I and II introns, Ribonuclease P, hepatitis D
virus, as well as the hairpin and hammerhead ribozymes [41–43]. Ri-
bozymes can also be artificially created to act on specific target se-
quences in cis (intramolecular RNA catalysed reactions) or trans (in-
termolecular cleaving reactions, where other RNA molecules act as
substrate) [44].
The two types of ribozymes that have been used most extensively
are the hairpin- and hammerhead-ribozymes. This study employed
hairpin ribozymes. The hairpin ribozyme consists of two independently
folding domains, A and B, which must interact through tertiary contacts
to form a functional catalytic complex (Fig. 1). After having cleaved the
substrate RNA in the region that forms part of loop A (Fig. 1), the ri-
bozyme dissociates from its substrate. The ribozyme can thereafter
hybridise to and cleave new substrate RNA molecules. This reaction
does not require protein cofactors [45]. However, the nucleotides
within the internal loops are critically important for generating the
required structure that forms an active site for the reaction [46].
A carefully designed antisense RNA selectively targets the mRNA
encoded by an individual gene, thereby inhibiting the expression of the
corresponding protein. By binding to its substrate mRNA, an antisense
RNA can translationally inactivate this mRNA, leading to knock-down
of the corresponding protein. It has been hypothesised that the asso-
ciation of an mRNA with a complementary sequence could specifically
block the synthesis of the encoded protein in a dose-dependent manner,
as the formation of a double-stranded hybrid would prevent the
message from being translated by ribosomes. The prevention of ribo-
somal assembly or ribosomal sliding along the mRNA molecule also
appears as possible important mechanisms of antisense action [47].
AnxA2 has been suggested by several studies to be a potential
therapeutic target for the treatment of cancer in general, as well as for
targeting metastasis and cancer-associated drug resistance [48,49].
Inhibition of angiogenesis has been targeted by inactivation of the
vascular endothelial growth factor (VEGF). However, this type of
therapy caused severe side effects due to the formation of more invasive
and metastatic tumours [50]. As AnxA2 is involved in both angiogen-
esis and metastasis [51–53], therapeutic targeting of AnxA2 in cancer
cells/cancer associated tissues could dramatically reduce most or all of
these side effects. The highly potent ribozyme designed against rat
anxA2 mRNA can easily be adapted to human anxA2 mRNA and further
developed for delivery by a viral infection system targeting cancer cells,
or using an RNA nanotechnology approach [54].
2. Materials and methods
2.1. Construction of ribozymes
The purified N-ras-pMJT plasmid, originally harbouring a cDNA
coding for a hairpin ribozyme against HIV-1 [55], was used as a tem-
plate for PCR amplification of the catalytic sites of the ribozymes
against anxA2 mRNA. The use of five different specific 5′ primers (the
specific 5′end primer for the very active RatRib120 is 5′-acaggatcc-
tagggtttagaacataaccagagaaacacacgtt with the BamHI site underlined;
the other forward primers are: RatRib116, 5′-acaggatccgtttgactagaaca-
taaccagagaaaca cacgtt; BovRib128, 5′-acaggatccctttgactagaacgtaacca-
gagaaacacacgtt; BovRib132, 5′-acaggatcctacgctttagaagaccaccagagaaa-
cacacgtt; BovRatRib389/401, 5′-acaggatcctcttcagtagaactttaccagaga-
aacacacgtt) resulted in the amplification of five different anxA2 ribo-
zymes. However, the same 3′ end primer was used in all PCR amplifi-
cations, namely 5′-aaaacgcgtaccaggtaa with the MluI site underlined.
Thus, the specificity of the hairpin ribozyme cDNA in the expression
cassette between the tRNA promoter and the tRNA termination se-
quences in the pMJT vector [56] was changed. All primers were from
GenoSys, Sigma-Aldrich (USA). The ribozyme constructs were also in-
serted in the TOPO vector under the control of the T7-promoter for in
vitro assays in the rabbit reticulocyte lysate system. Furthermore, the
entire expression cassettes containing the two different constructs
(anxA2 RatRib120 or antisense RNA) were excised from the pMJT
Fig. 1. The structural framework of the trans-acting
anxA2 RatRib120 hairpin ribozyme and its sub-
strate. Helices 1 and 2 are responsible for substrate
recognition and loop A, which has certain base re-
quirements (see text for further details), contains the
cleavage site. Loop A is formed by both the ribozyme
and target mRNA. Two helices, helix 3 and helix 4,
separate a large asymmetrical internal loop, the loop
B, and are entirely of ribozymal origin.
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vector and inserted into the HindIII site of the pJIM vector, which
contains the cDNA encoding the enhanced green fluorescence protein
(eGFP) under the control of a CMV promoter. All constructs were ver-
ified by sequencing.
2.2. Cloning of cDNAs coding for rat anxA2 mRNA and antisense RNA
There are two variants of rat anxA2 mRNA; a 1356 nucleotide (nt)
form and a 1362 nt form, which have probably arisen through alter-
native splicing of the gene [57]. A consecutive sequence of 6 nt in the
5′end of the coding region of the anxA2 mRNA constitutes the only
difference between the two forms, which otherwise show a homology of
100%. The introduction of 6 extra nt results in 2 extra amino acids,
including a Ser in the N-terminal domain of rat AnxA2 [57]. The
1356 nt form of rat anxA2 was obtained by RT-PCR using total RNA
isolated from PC12 cells. It should be noted that the more abundant
isoforms of mRNAs are preferred by this method [58]. PC12 cells were
used as the source of good quality total RNA isolated by the use of
TRIzol reagent (Thermo Fisher Scientific, USA), followed by RNA pre-
cipitation from the aqueous phase. First strand cDNA synthesis was
performed using the SuperScript II RNase H-Reverse Transcriptase kit
(Thermo Fisher Scientific, USA) and mRNA was degraded by RNase H
(Thermo Fisher Scientific, USA). Second strand synthesis was per-
formed with the GC-RICH PCR System kit (Sigma-Aldrich; USA). The
specific primers were ratBamH1-forward (5′-cgtggatccggaggctctctgcaa-
taggt) and ratHindIIIreverse (5′-cgaagcttttttttttttttttaaag). The full-
length rat anxA2 cDNA (including the UTRs) was inserted into the
BamHI and HindIII sites in the transcription pGEM3Z(f)+ vector (Pro-
mega, USA) under the control of the T7 promoter. For the construction
of the cDNA coding for the 141 nt rat antisense anxA2 RNA, full-length
rat anxA2 cDNA was used as a template with the primers ratMlu1for-
ward (5′-taacgcgtggaggctctctgcaataggt) and ratanx143BamHIreverse:
(5′-taggatccgaagttggtgtagggtttga). The rat anxA2 antisense cDNA was
also inserted in the expression cassette in the MluI and BamHI sites of
the pMJT vector, as well as in the TOPO vector similar to the ribozymes.
The expression cassette was subsequently inserted into the BamHI site
of the pJIM vector. Restriction enzymes were obtained from Thermo
Fisher Scientific (USA). All cDNA constructs were verified by sequen-
cing.
2.3. Culture and infection of PC12 cells
The rat adrenal pheochromocytoma (PC12) cells, representing a
readily adherent sub-clone derived from the original PC12 cell line [59]
(a generous gift from professor Jaakko Saraste), were grown in Gibco
RPMI 1640 medium (Thermo Fisher Scientific, USA) supplemented
with 10% (v/v) heat-inactivated horse-serum, 5% (v/v) foetal bovine
serum, 2mM L-glutamine, 100 units penicillin/ml and 100 µg strepto-
mycin/ml. All supplements were from Sigma-Aldrich (USA). As de-
scribed previously [60], the cells were routinely cultured at 37 °C in a
humidified atmosphere of 21% O2 supplemented with 5% CO2. For
transfer of the cDNAs encoding the ribozyme and the antisense RNA
into the genome of the PC12 cells, a retroviral packaging system using
the ecotropic Phoenix cell line was used [61]. The genome of murine
retroviruses (Moloney murine leukaemia virus) consists of three genes:
The capsid-group antigen (gag), polymerase (pol) and envelope gene
(env) flanked on both sides by LTRs. Phoenix is an amphotropic 293T-
based split packaging cell line and has the gag-pol and env genes each
expressed from a different non-Moloney murine leukaemia virus-based
promoter. Phoenix packaging cells provide the structural and reg-
ulatory proteins necessary for assembling an infectious viral particle.
The retroviral vector (the recombinant pJIM vector containing the in-
serted ribozyme or antisense RNA sequence in the expression cassette),
was mixed with calcium chloride (Sigma-Aldrich, USA) and HEPES-
buffered saline to form a precipitate. The packaging cell line took up the
precipitate and the plasmid was transcribed. The retroviral vector also
contains a packaging signal, which causes the Phoenix cells to assemble
virus particles “loaded” with the recombinant pJIM. These particles bud
from the host cells and can be collected and used to infect the target
cells – in this case, the PC12 cells. PC12 cells express the murine multi-
spanning membrane protein that is the retroviral receptor recognised
by the envelope protein of Moloney murine leukaemia virus and re-
quired for the infection of virions harbouring this envelope protein.
Infection involves the binding of the retroviral env to this specific cell
surface receptor in the PC12 cells, resulting in the internalisation of the
complex. Once inside the cell, the viral nucleoprotein complex gains
access to intracellular DNA nucleotide triphosphate pools, whereupon
the retroviral reverse transcriptase initiates the synthesis of a double-
stranded DNA copy of the viral genome, in preparation for its in-
tegration into the host cell chromosome. For this purpose, the linear
double-stranded cDNA made in the cytoplasm is first transported to the
nucleus. It is subsequently inserted into the host genome due to the
presence of the LTRs in the cDNA and the viral enzyme Integrase. In-
fection of a host cell with a retrovirus results in the establishment of a
lifelong carrier state because the virus remains integrated as provirus
within the chromosome of the infected cell.
2.4. Selection of the infected cells using FACS
Infected PC12 cells were separated from uninfected PC12 cells by
two-way flow-cytometry using Cytomation’s MoFlo modular flow cyt-
ometer with a 70 µm nozzle. The PC12 cells infected (5–25% efficiency)
with the RatRib120 ribozyme, the antisense anxA2 construct, or the
empty pJIM vector were grown in culture to reach approximately 70%
confluency. The total amount of cells was estimated to 1.5×106. The
cells were mechanically detached from the flasks, transferred to cen-
trifuge tubes, and centrifuged at 500g for 5min. The supernatant was
discarded, and the pellet resuspended in 1ml of Gibco RPMI 1640
medium (Thermo Fisher Scientific, USA) containing 2mM L-glutamine,
10% (v/v) heat-inactivated horse serum, 5% (v/v) foetal bovine calf
serum, 100 u/ml penicillin and 100 µg/ml streptomycin. All supple-
ments were from Sigma-Aldrich (USA). The cell suspension was placed
in the MoFlo Cytomation apparatus and sorted according to the manual
provided by the manufacturer. Subsequently, the cells were seeded in
96-well plates at low density to obtain uniform cultures of infected
cells.
2.5. Preparation of cell lysates from PC12 cells
Whole PC12 cell lysates were obtained by incubation of cells for
15min in RIPA buffer (Thermo Fisher Scientific, USA) with 2mM EGTA
(Sigma-Aldrich, USA) and protease inhibitor cocktail (Roche,
Mannheim, Germany; EDTA-free), followed by centrifugation for
20min at 12,000g, as detailed in Aukrust et al. [62]. Protein determi-
nation was performed using the infrared spectroscopy method and Di-
rect Detect® Infrared Spectrometer according to the manufacturer
(Millipore, USA).
2.6. SDS-PAGE and western blot analysis
SDS-PAGE was performed using 10% (w/v) gels (Mini-Protean TGX;
Bio-Rad Laboratories, USA) and the proteins were transferred onto ni-
trocellulose membranes (0.2 µm pore size) (Amersham, GE Healthcare
Life Science, Germany) by blotting performed at 50 V for 2 h. AnxA2
(610069; BD Biosciences (USA); dilution 1:1000), AnxA7 (610668; BD
Biosciences (USA); dilution 1:1000) and tubulin (86298; Cell Signaling
Technology (USA); dilution 1:5000) were detected by mouse mono-
clonal antibodies, while AnxA1 was detected by rabbit polyclonal an-
tibodies (71-3400; Invitrogen (USA); diluted 1:500). AnxA11 was de-
tected by goat polyclonal antibodies (sc-9322; Santa Cruz
Biotechnology (USA); dilution 1:500). Subsequently, horseradish per-
oxidase (HRP)-conjugated anti-mouse, anti-rabbit or anti-goat
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secondary antibodies (Bio-Rad Laboratories (USA) or Abcam (UK))
were used. The reactive protein bands were visualised using the
WesternBright ECL HRP substrate (Advansta, USA).
2.7. Coupled transcription/translation reactions in the rabbit reticulocyte
lysate (TNT)
The TNT reticulocyte lysate system (Promega, USA) was used to
perform a coupled transcription/translation reaction to determine the
effect of the different ribozymes and the antisense RNA on the ex-
pression of the rat AnxA2, measured as [35S]-Met (10mCi/ml) (Perkin
Elmer, USA) incorporated into the protein. Circular plasmid DNA (1 µg
of each) was used as templates. The plasmids with cDNAs coding for the
ribozymes or the antisense RNA were pre-incubated for 10min to in-
itiate their transcription before the plasmid containing the rat anxA2
cDNA (or control vector with the luciferase cDNA) was added to the
reaction. The samples were incubated for a further 90min at 30 °C.
0.2 mg/ml RNase A (Thermo Fisher Scientific, USA) was added to the
samples, which were then incubated for another 5min at 30 °C. The
newly synthesised proteins were resolved by 10% SDS-PAGE and vi-
sualised using a Canberra Packard Instant Imager (Austria).
3. Results
3.1. Design of ribozymes and an antisense RNA against rat annexin A2
mRNA
We designed ribozymes against both rat and bovine anxA2 mRNA.
However, the latter were not used in infection studies due to the lack of
a suitable bovine cell line. Instead, the ribozymes directed against bo-
vine anxA2 mRNA served as controls of the specificity of the ribozymes
against rat anxA2 mRNA. The first part of the name of the ribozyme
indicates the species of the substrate mRNA, while the following
number indicates the position of the nt immediately next to the 5′ end
of the point of cleavage in the substrate mRNA, based on the rat and/or
bovine anxA2 cDNA sequences (NM_019905.1 and NM_174716.1, re-
spectively) (Fig. 1). Altogether 5 ribozymes (Rib) were designed: Ra-
tRib116, RatRib120, BovRib128, BovRib132 and RatBovRib389/401
(Fig. 2). In order to determine the specificity of the three rat anxA2
ribozymes, different features were adopted in their design. Thus, it
should be noted that RatRib116 has full base-pairing in helices 1 (7 bp)
and 2 (4 bp) and a loop A of 10 nt in total, while RatRib120 has full
base-pairing in helix 1 (8 bp), a loop of 8 nt in total, but only one base-
pairing in helix 2. Furthermore, RatBov389/401 has only 6 bp in helix 1
and full base-pairing in helix 2 (4 bp) and a large loop A (12 nt in total).
However, loop A in RatBov389/401 does not contain the G that is
supposed to be important for cleavage of the mRNA. A hairpin ribo-
zyme is supposed to have a substrate sequence requirement of 5′-
BN * GUC-3′ in the part of loop A formed by the substrate mRNA, where
the * indicates the site of cleavage, the nucleotide B is G, U or C, and N
is any base [63]. The BovRib128 has no match to the rat anxA2 mRNA
in the region forming helix 2 and BovRib132 has no significant match to
rat anxA2 mRNA (Fig. 2).
A target region in the rat anxA2 mRNA comprising the first 141 nt
starting from its very 5′ end was selected for designing the rat anxA2
antisense RNA sequence. Specific primers were designed to amplify the
cDNA sequence corresponding to this region in the antisense direction.
It has been considered preferable that the target region resides in the 5′
end of the mRNA, comprising the AUG start codon [64], in order to
inhibit or hamper initiation of translation.
3.2. In vitro effects of the anxA2 ribozymes and antisense RNA on rat
anxA2 mRNA stability/translatability
The different ribozyme and antisense RNA constructs were inserted
into the TOPO vector in the correct orientation relative to the T7
promoter. Subsequently, their effect on the rat anxA2 mRNA stability/
translatability was analysed in the rabbit reticulocyte lysate (TNT
system) by monitoring the incorporation of [35S]-Met into AnxA2 pro-
tein following T7-driven transcription of the rat anxA2 mRNA from its
cDNA in the pGEM3Zf(+) vector, and its subsequent translation
(Fig. 3A, D). The incorporation of [35S]-Met after coupled transcrip-
tion/translation of the rat anxA2 cDNA alone (lane 1) was used as
control (100%), while the co-transcription of the ribozymes resulted in
either no significant effect (BovRib128; lane 2), (BovRib132; lane 3),
(RatRib116; lane 4) or reduction in the incorporation of [35S]-Met into
AnxA2 by approximately 90% (RatRib120; lane 5) or 70% (Rat-
BovRib389/401; lane 6), respectively, as compared to the transcrip-
tion/translation of anxA2 mRNA alone (100%) (Fig. 3A, C). The effect
of the different ribozyme transcripts on the synthesis of a 61 kDa luci-
ferase protein was used as negative controls (Fig. 3B).
The rat anxA2 antisense RNA sequence led to a ∼70% decrease of
AnxA2 expression in the coupled transcription/translation system
(Fig. 3D and F, compare lanes 7 and 8). The expression of the luciferase
protein was again used as a control (Fig. 3E). Despite the appearance of
Fig. 2. The 5′ end of the different ribozymes directed against rat and/or bovine
anxA2 mRNA. Only the nucleotides of the ribozymes complementary to the rat
anxA2 substrate mRNA and the ribozymal nucleotides involved in forming loop
A are shown. The names of the ribozymes indicate whether the ribozyme is
designed to cleave rat or bovine anxA2 mRNA, and also provides the position of
cleavage in the substrate mRNA.
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some degradation products below the main band of ∼61 kDa, the in-
tensity of the luciferase bands did not decrease in the presence of the rat
anxA2 antisense RNA (lane 8).
When using the coupled in vitro transcription/translation rabbit
reticulocyte system it was important to establish and quantify the
presence of AnxA2 in the lysate. Although only newly synthesised
AnxA2 will contain [35S]-Met, the presence of endogenous AnxA2 in the
lysate might interfere with the results obtained using this in vitro
system, since AnxA2 binds to its cognate mRNA [65]. It is evident from
Fig. 4, lanes 1–3 that the rabbit reticulocyte lysate does not contain
endogenous AnxA2. This corroborates the findings of others showing
that AnxA2 is not present in erythrocytes [66].
3.3. Transfer of anxA2 antisense and RatRib120 constructs into a retroviral
vector expressing GFP allows visualisation of infection and sorting of
infected PC12 cells
The rat pheochromocytoma PC12 cell line is useful for morpholo-
gical studies since they are rather flat and become polarised during
differentiation, being particularly well suited for confocal microscopy.
Finally, contributing to the usefulness of transfections and/or infections
is their relative stability, homogeneity, high efficiency of differentiation
in response to nerve growth factor (NGF), potential for genetic ma-
nipulation and the large number of studies characterising their prop-
erties.
As the RatRib120 ribozyme proved to be the most effective in the in
vitro experiments employing the TNT coupled transcription/translation
system, it was chosen for further testing in PC12 cells. In order to
perform infection experiments with the two cDNAs, encoding either the
RatRib120 ribozyme or the antisense RNA under the control of a tRNA
Fig. 3. The effect of anxA2 hairpin ribozymes (A) or antisense RNA (D) on the translation of rat anxA2 mRNA (A and D) in a coupled transcription-translation in vitro
system (TNT). anxA2 mRNA was transcribed and translated from 1 µg of pGEM3Zf(+) vector containing the rat anxA2 cDNA alone (lanes 1 and 7), or in combination
with the transcripts BovRib128 (lane 2), BovRib132 (lane 3), RatRib116 (lane 4), RatRib120 (lane 5), RatBovRib391/401 (lane 6), or of rat anxA2 antisense RNA
transcribed from 1 µg of recombinant TOPO vector. Similar experiments were performed using 1 µg of Control Vector containing the luciferase cDNA as a negative
control, as indicated in the Figure (B and E). [35S]-Met labelled AnxA2 was resolved by 10% SDS-PAGE, and visualised using a Canberra Packard Instant Imager. 10 µl
reaction mix was applied in each well. The 36 kDa AnxA2 and the 61 kDa luciferase are indicated by arrows to the left. Results (C and F) are the mean ± SD of 3
independent experiments each. Statistical significance was determined by the unpaired Student’s t-test (*p < 0.05).
Fig. 4. The absence of endogenous AnxA2 in rabbit reticulocyte lysate. Proteins
in 50 µg (lane 1), 100 µg (lane 2), or 150 µg (lane 3) rabbit reticulocyte lysate or
increasing amounts of purified AnxA2 tetramer; 0.5 µg (lane 4), 1.0 µg (lane 5),
2.0 µg (lane 6) and 3.0 µg (lane 7), to serve as a standard curve for AnxA2, were
separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane.
Subsequently, AnxA2 was immunodetected by affinity purified monoclonal
AnxA2 antibodies.
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promoter, they were inserted into the retroviral pMJT vector between
the tRNA promoter site for polymerase III and the tRNA termination
sequence using MluI and BamHI restriction enzymes [55]. Subse-
quently, the resulting expression cassettes containing the two different
constructs were excised from this vector and inserted into the pJIM
vector, which also contains the cDNA encoding eGFP, and therefore
could be used as a reporter gene for the identification of infected PC12
cells. pJIM also contains a CMV promoter and is a CRU5-GFP variant
described in [56].
The PC12 cells infected with the RatRib120 cDNA together with the
eGFP marker did not survive the infection despite several attempts.
However, the in vitro assays showed that we had designed a very active
ribozyme by making the helix region 2 formed by the ribozyme to-
gether with the mRNA very flexible in just having one base-pairing.
The PC12 cells infected with the cDNA coding for the 141 nt rat
anxA2 antisense RNA sequence together with the eGFP marker sur-
vived. Approximately 25% of the PC12 cells in the infected cultures
displayed green fluorescence (Fig. 5), indicating positive infection with
the anxA2 antisense construct. Both PC12 cells infected with the eGFP
marker only, and cells infected with eGFP together with the anxA2
antisense RNA, were sorted by FACS (Fig. 6) in order to study the effect
of the anxA2 antisense RNA on the expression of AnxA2 in rat PC12
cells. The cells from each culture were sorted separately using two-way
sorting based on eGFP expression of the infected cells.
3.4. Specificity of the anxA2 antisense RNA
Immediately following the infection with the anxA2 antisense RNA,
the infected PC12 cells were not able to respond to NGF and initiate the
outgrowth of long neurite-like extensions. This was expected since
AnxA2 has been reported to play a role in the outgrowth of PC12 cell
extensions [67] and is also present in their growth cones [68]. How-
ever, after some passages, many of the cells that were infected with the
antisense RNA formed long extensions, also in the absence of NGF,
which was completely unexpected. The analysis of cell lysates prepared
from wild-type PC12 cells, cells infected with an empty vector (pJIM),
or anxA2 antisense RNA in the same vector, showed that AnxA2 is
down-regulated in cells infected with the antisense construct (Fig. 7A,
lane 3), in particular when compared with the empty vector control
(Fig. 7A, lane 2). It should be noted that infection with the empty vector
alone evidently causes up-regulation of AnxA2 expression, perhaps due
to the presence of the strong CMV promoter in the vector. As AnxA1 is
the closest relative of AnxA2 [1], we hypothesised that there could be a
redundancy between AnxA1 and AnxA2 functions in the infected cells.
Thus, we also investigated the expression level of AnxA1 and two more
distantly related Anxs; namely AnxA7 and AnxA11. It is evident that
neither AnxA1 (Fig. 7A-B, lane 3) nor AnxA11 (Fig. 7A-B, lane 3) is
upregulated following AnxA2 knock-down, while the expression of
AnxA7 is about 6-fold upregulated (Fig. 7A-B, lane 3).
Fig. 5. Cultured PC12 cells infected with the rat anxA2 antisense cDNA together with the eGFP marker. PC12 cells after infection as seen with normal light (A), or
with a blue light (B). The two images are merged in C. The positive infected PC12 cells can be seen as green fluorescence specs, due to the expression of the eGFP
marker, whereas the uninfected cells do not express eGFP.
Fig. 6. Graphic recordings of the PC12 cells during the sorting process, indicating the level of fluorescence (FL1) and granulation (SSC) in uninfected PC12 cells
(graph 1), PC12 cells infected with the eGFP marker alone (graph 2), or a combination of the eGFP marker and the rat antisense anxA2 (graph 3). Graphs 1–3 were
recorded using cycle mode as the cells pass through the flow-cytometer, and display the distribution of fluorescent cells versus non-fluorescent cells at any given time.
Two areas (R1 and R5) were marked in each of the graphs, and the cells within these two areas were sorted using two-way sorting as the fluorescent cells (R5) were to
be sorted from the non-fluorescent cells (R1). The R5 and R1 population of cells were collected in separate tubes, and the R5 population containing PC12 cells
infected with both the eGFP marker and the rat antisense anxA2 RNA was used for further applications.
E. Aareskjold, et al. Biochemical Pharmacology 166 (2019) 253–263
258
4. Discussion
4.1. Design of ribozymes and their efficiency in vitro in the coupled
transcription/translation system
Due to their catalytic effects in cleaving specific mRNAs, ribozymes
have been regarded as promising tools both in basic research and dis-
ease therapy. Several ribozymes have already been used in the treat-
ment of infectious diseases, cancer and genetic disorders. Recently, ri-
bozymes have also been used in transgenic animal research, as well as
gene target validation and pathway elucidation. One of the advantages
of using ribozymes is that their effect is equivalent to a gene knock-out
without the need for homologous recombination and inactivation of
both alleles [69].
Several investigators have stated the need for the nucleotide G in
position 11 of the ribozyme sequence, which forms the first base pair in
helix 2, next to loop A [63,70–72]. However, of the ribozymes gener-
ated in this project, only BovRib132 has the nucleotide G in position 11.
By contrast, all the remaining ribozymes have C in this position, in-
cluding RatRib120 with the highest cleavage activity and thus the
strongest knock-down effect on rat anxA2 mRNA (Figs. 1 and 2). Only
ribozyme RatRib116, contains full complementarity to the rat anxA2
mRNA within the 4 nt helix 2 segment, whereas the highly effective
RatRib120 ribozyme is only capable of Watson-Crick base-pairing to
one nt in the target mRNA within this region (Figs. 1 and 2). The high
efficiency of the RatRib120 ribozyme (Fig. 2) could be caused by
greater freedom of the hinge region, as there is no “constraining”
complementarity in the helix 2 region. This could allow a more precise
interaction between the loop A and loop B domains of the ribozyme (see
Fig. 1), which is required for its catalytic activity. However, it is gen-
erally considered that helix 2 should be fixed at 4 bp for optimal ac-
tivity, whereas the length of helix 1 giving optimal catalytic efficiency
is dependent on its sequence and must be optimised for each target
sequence [73]. Since flanking sequences of 5–9 bp typically yield op-
timal activity, all five anxA2 mRNA specific ribozymes contain 7–8 nt,
which hybridise to the target mRNA to form helix 1.
The coupled in vitro transcription/translation system based on the
rabbit reticulocyte lysates closely mimics in vivo conditions, containing
all the necessary components for efficient synthesis of proteins. This
system has been used with success to analyse the effect of ribozymes
and antisense RNA on target mRNAs [74]. Thus, it is also suitable for
testing the effect of anxA2 specific ribozymes and antisense RNA on the
translation of rat anxA2 mRNA. In this coupled transcription/transla-
tion system, the ribozyme constructs directed against rat anxA2 mRNA
(RatRib116 and RatRib120) were more specific for their substrates than
the ribozyme constructs directed against bovine anxA2 mRNA
(BovRib128 and BovRib132) (Fig. 3). The RatRib120 and BovRib132
ribozymes resulted in higher knock-down efficiency of rat anxA2 mRNA
as compared to the RatRib116 and BovRib128 ribozymes, respectively.
Both pairs of ribozymes were directed against two homologous sites in
the respective mRNAs. Accordingly, the different catalytic activities of
these pairs might be caused by better accessibility of the RatRib120 and
BovRib132 ribozymes to their substrate, due to the secondary structure
of the anxA2 mRNA. The ribozyme directed against a region common to
both rat and bovine anxA2 mRNAs, BovRatRib389/401, was also quite
effective in inhibiting the translation of rat anxA2 mRNA. The anxA2
specific ribozymes did not affect the synthesis of luciferase serving as a
negative control, indicating a certain degree of specificity. In conclu-
sion, all the three ribozymes targeting specifically the rat anxA2 mRNA
were very efficient in the knock-down of rat AnxA2 expression in vitro.
4.2. Efficiency of the rat anxA2 antisense RNA and ribozymes in the in vitro
coupled transcription/translation system and upon retroviral infection of
PC12 cells
The rat anxA2 antisense RNA leads to about 70% reduction in
AnxA2 expression in the reticulocyte lysate-based coupled transcrip-
tion/translation system (Fig. 3D, compare lanes 7 and 8). Thus, the
antisense was selected for retroviral infection of PC12 cells. All the
PC12 cells used in this project are derived from the same sub-clone,
which is an important requirement since different sub-clones of PC12
cells vary in their ability to form extensions upon stimulation with NGF.
In order to transcribe the ribozymes and the antisense RNA se-
quence under the control of a strong promoter, the cDNA constructs
were ligated into an expression cassette containing a tRNA promoter
and a tRNA termination sequence. The promoter present in the ex-
pression cassette is an RNA polymerase III promoter shown to yield
very high intracellular levels of ribozymes, in addition to providing a
high transcription rate and stability of the mature ribozyme transcript
[75]. Promoters naturally involved in the synthesis of small RNAs, like
tRNAs and snRNAs, have well-defined transcription termination signals
and thus can transcribe short artificial sequences with well-defined
Fig. 7. Expression levels of Anxs A1, A2, A7 and A11 in PC12 cells after in-
fection with rat anxA2 antisense RNA. 20 µg of total cell lysates from control
cells (lane 1), cells infected with empty pJIM vector (lane 2) or with rat anxA2
antisense RNA in pJIM (lane 3) were separated by 10% SDS-PAGE and trans-
ferred to nitrocellulose membranes and probed against AnxA1, AnxA2, AnxA7
and AnxA11 as indicated to the right. Probing against tubulin was used as a
loading control. Results (B) are the mean ± SD of 3 independent experiments
each. Statistical significance was determined by the unpaired Student’s t-test
(*p < 0.05).
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flanking sequences. A retroviral vector (pMJT) containing a strong
tRNA promoter was chosen for this study. Furthermore, in the course of
the project, a retroviral vector containing the eGFP cDNA (pJIM) be-
came available. Since eGFP would also serve as a good transfection/
infection marker, the ribozyme expression cassette with the tRNA
promoter was cloned into this vector. The retroviral pJIM vector con-
tains a multiple cloning site just upstream of the eGFP gene within a
region of the plasmid flanked by LTRs and the viral packaging signal.
This vector was used to transfect the Phoenix cell lines which would
package the region flanked by the LTRs into replication-defective viral
particles.
The intracellular transcription of a ribozyme or an antisense coding
gene is termed endogenous ribozyme/antisense delivery. Alternatively,
ribozymes or antisense RNAs can be introduced either by direct injec-
tion or by transfection. Endogenous delivery of ribozymes and the an-
tisense RNA, as carried out in this project, requires a vector, preferably
a retroviral one, containing the gene for the ribozyme or antisense
controlled by a suitable promoter. Transcription of the ribozyme or
antisense can then be achieved either in stably infected or transiently
transfected cell lines. It is very important that the ribozyme or antisense
gene is placed downstream of a strong promoter, resulting in its effi-
cient expression, as the high cellular concentration of ribozyme or an-
tisense ensures that substrate binding is not a limiting factor. This also
introduces a higher risk for off-target effects. The major advantage of
the endogenous application of ribozymes and antisense lies in their
continuous expression. Both are transcribed in the nucleus and trans-
ported into the cytoplasm [76]. The in situ production of the regulatory
agent, and hybridisation between the ribozyme/antisense RNA and
messenger RNAs, may take place within the nucleus or in the cyto-
plasm. Therefore, effects on gene expression might occur after tran-
scription, but prior to translation [77]. In the infection experiments
carried out in this project, the DNA sequence, which was inserted into
the host DNA, consists of the 5′LTR, followed by the packaging signal
(Ψ), the tRNA promoter, the cDNA of interest (encoding either the
RatRib120 ribozyme or the rat anxA2 antisense RNA), the tRNA ter-
mination sequence, the eGFP encoding gene and the 3′LTR. The ribo-
zyme is under direct control of the tRNA promoter.
4.3. Retroviral infection with the RatRib120 ribozyme
In vitro experiments assessing the effect of the RatRib120 ribozyme
on the translation of rat anxA2 mRNA showed approximately 90% re-
duction when using the translation of rat anxA2 alone as a reference.
The RatRib120 ribozyme was expected to be more effective in vivo than
in vitro because cells contain a number of unwinding activities that may
give the ribozyme better access to the target mRNA. The transfection of
the Phoenix cell line with the retroviral vectors was successful, resulting
in efficient production of virus particles containing the RatRib120 ri-
bozyme cDNA. Nevertheless, the three separate infections of PC12 cells
with the RatRib120 ribozyme resulted in only a few weakly eGFP-po-
sitive cells, which died within 30–40 h after infection. The AnxA2
protein has a lifespan of approximately 15 h [78]. Thus, one possible
explanation for the observed cell death is that the AnxA2 protein is vital
to PC12 cells. Since the AnxA2 knock-out mice are viable, devel-
opmentally normal and have a normal lifespan [79], PC12 cell death
due to the ribozyme infection was unexpected. Infection with the empty
pJIM vector (which only contains the cDNA for eGFP between the LTRs)
did not kill the cells; neither did the infection with anxA2 antisense
RNA, suggesting that cell death was related to the ribozyme. It is pos-
sible that the ribozyme construct was inserted via the LTRs into a site in
the host DNA, which activated certain strong promoters. As a con-
sequence, increased expression of proteins compromising cell viability
could be activated. Since it is not likely that the anxA2 ribozyme cDNA
was inserted into the same site in all cells (although insertion is not a
completely random event), it is more likely that the ribozyme also
targets other mRNAs and in this manner causes cell death. A Blast
(megablast) of the target substrate sequence of RatRib120, namely 5′-
ggucggucaaacccua, did not give a full match to any other sequences
than to anxA2 cDNA or pseudogene. Since it is possible that the ribo-
zyme binds partially to sequences, thus creating off-target effects, such
effects can also be expected for small RNAs including the guide RNA
employed in the CRISPR/Cas9 technology. Namely, there is no re-
quirement for a 100% hybridisation between the mRNA and the ribo-
zyme/small RNA. However, there is still another possibility which is not
related to off target effects; namely, in the AnxA2 knock-out mouse the
expression of genes can be subject to adaptation during development.
Thus, the knock-out mouse can over time gain the ability to survive due
to compensatory effects, while knock-down cells loaded with a highly
active ribozyme are left with no choice or enough time for similar
adaption. The findings showing that in the AnxA1 knock-out mouse,
several other Anxs are upregulated (depending on the tissue), giving
rise to redundancy/compensatory effects, corroborate this possibility
[80]. Our primary goal was to knock-down AnxA2 in viable cells.
Preliminary in vitro experiments in which the effect of RatRib120 was
tested on radiolabelled anxA1, anxA7 or anxA11 mRNAs showed no
effect on these mRNAs, indicating a certain degree of specificity (results
not shown). This does not rule out that other off-target mRNAs could be
involved. However, this is a problem, which should be considered in all
knock-out and knock-down experiments.
4.4. Retroviral infection with the anxA2 antisense RNA
The infection studies also demonstrated the survival of the PC12
cells infected with the rat anxA2 antisense RNA, although cell pro-
liferation was decreased as compared to uninfected PC12 cells or PC12
cells infected with the eGFP marker only. For further investigation, the
infected cells were sorted using FACS to obtain a homogenous popu-
lation of anxA2 antisense-infected PC12 cells, as well as of control PC12
cells infected with the eGFP marker only (Figs. 5 and 6).
Generally, the infected cells appeared larger than the uninfected
cells. Furthermore, the increase in size was more apparent in cells in-
fected with the rat anxA2 antisense RNA. A possible explanation might
lie in the fact that AnxA2 anchors the cortical actin cytoskeleton to the
plasma membrane [80]. Thus, due to down-regulation, this anchoring
function could be compromised in the PC12 cells expressing the rat
anxA2 antisense RNA. Consequently, the interaction between the cor-
tical actin network and the plasma membrane would become less tight,
resulting in an apparent increase in cell size. In accordance with this
idea, it has been shown that many cells contain a large AnxA2 pool just
underneath the plasma membrane [1,81].
There was a marked decrease in the expression of AnxA2 in the
PC12 cells infected with the eGFP marker together with the rat anxA2
antisense RNA as compared to PC12 cells infected with eGFP alone.
Thus, the antisense RNA indeed inhibited the translation of the rat
anxA2 mRNA in these cells, resulting in decreased endogenous AnxA2
levels that could affect the ability of the cells to grow at a normal rate.
However, the uninfected PC12 cells expressed AnxA2 at a level that was
lower than that observed in cells infected with the eGFP marker alone
(Fig. 7). A likely explanation could be that the insertion of the eGFP
marker is quasi-random. It is possible that its insertion enhances the
transcription of AnxA2 directly or via other transcription factors.
4.5. Ribozymes and antisense RNAs as tools to knock-down target mRNAs
As ribozymes can act catalytically by destroying a particular mRNA,
they might be more efficient tools to down-regulate the expression of a
particular gene than an antisense RNA, which cannot recycle. An an-
tisense RNA does not dissociate from the RNA substrate, thereby
blocking its translation. A 1:1 ratio between an antisense RNA-molecule
and its mRNA substrate is therefore theoretically required to achieve a
complete inhibition of a specific gene. However, antisense RNAs can
also act via an enzymatic mechanism by inducing the activity of RNase
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H [82]. Thus, although these antisense RNAs are not inherently cata-
lytically active, they could induce such an activity. Our studies showed
that the rat anxA2 antisense RNA inhibited the expression of rat AnxA2
by 70% in a coupled in vitro transcription/translation assay. This in-
hibition was higher in vivo, indicating that more factors are operational
in the PC12 cells than in the rabbit reticulocyte lysate system used for
the in vitro assays. In addition, all ribozyme constructs contain two
regions forming helices 1 and 2 together with the target mRNA by
hybridisation and could thus evoke an antisense RNA effect.
When uninfected PC12 cells were treated with NGF, they formed the
long extensions typical for neuron-like differentiation. However, when
the cells were first infected with rat anxA2 antisense RNA, they were
initially unable to form such long extensions. However, after several
passages, the infected cells formed extensions spontaneously. This
could be due to the upregulation of AnxA7, in line with results showing
its presence in dendrites [83]. Like AnxA2, AnxA7 is involved in the
organisation of the membrane cytoskeleton [84] and is present in lipid
rafts [85]. These overlapping functions of AnxA2 and AnxA7 could
explain the apparent compensatory effects of the latter.
AnxA2 knock-out mice have been produced [79,86]. The mice are
viable, but their cells show defects in membrane organisation and
transport along the secretory and endocytic pathways. In recent years,
there has been a concern regarding genetic compensation induced by
deleterious mutations, which has been suggested to be absent in gene
knock-downs [87]. The knock-down of AnxA2 resulting in the upre-
gulation of AnxA7 may indicate that compensation could take place
also as a knock-down effect.
4.6. Conclusions and future perspectives
In conclusion, the success of RatRib120 in knocking-down the ex-
pression of rat AnxA2 is due to the high catalytic effect of this ribozyme,
the accessibility of the target site in anxA2 mRNA, and its stable in-
tegration into host DNA. Its high catalytic effect is due to the very
flexible hinge region, helix 1, which is made by base-pairing with a
region of the mRNA. Several other studies have employed knock-down
of the expression of AnxA2 [88–92], but RatRib120 appears to be the
most efficient. The ribozyme can easily be adapted to target the human
anxA2 mRNA. The second most active anxA2 ribozyme, RatRib116,
targets a site only 4 nt away from that of RatRib120. Therefore, it may
be possible to generate a highly active and more specific ribozyme
against anxA2 mRNA by increasing the length of the 5′ end of the ri-
bozyme, thereby possibly avoiding off-target effects. Since ribozymes
have already been used in clinical trials with great success [93], this
ribozyme could provide a good candidate for optimisation and future
use as a therapeutic cancer drug. The anxA2 antisense RNA was less
efficient in knocking down the expression of AnxA2. Moreover, with
time, an upregulation of AnxA7 as a compensatory effect was observed,
showing how important it is to distinguish between short and long term
effects. Off-target and compensatory effects also apply in case of the
CRISPR/Cas9 technique [94], a novel method that still needs refine-
ment. Our preliminary experiments indicated that extracellular vesicles
isolated from PC12 cells infected with the anxA2 antisense RNA re-
duced the AnxA2 expression in PC12 cells infected with the empty
vector. As this finding opens the possibility that extracellular vesicles
from cell cultures infected with these RNAs can be harvested and ad-
ministrated to patients, this approach should be further explored and
refined in relation to virus infections, using an antisense RNA or a ri-
bozyme against viral RNA.
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